727 related articles for article (PubMed ID: 22498935)
21. Endometrial tumour BRAF mutations and MLH1 promoter methylation as predictors of germline mismatch repair gene mutation status: a literature review.
Metcalf AM; Spurdle AB
Fam Cancer; 2014 Mar; 13(1):1-12. PubMed ID: 23880961
[TBL] [Abstract][Full Text] [Related]
22. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
[TBL] [Abstract][Full Text] [Related]
23. Annexin A10 expression correlates with serrated pathway features in colorectal carcinoma with microsatellite instability.
Kim JH; Rhee YY; Kim KJ; Cho NY; Lee HS; Kang GH
APMIS; 2014 Dec; 122(12):1187-95. PubMed ID: 24909058
[TBL] [Abstract][Full Text] [Related]
24. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
[TBL] [Abstract][Full Text] [Related]
25. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification.
Parsons MT; Buchanan DD; Thompson B; Young JP; Spurdle AB
J Med Genet; 2012 Mar; 49(3):151-7. PubMed ID: 22368298
[TBL] [Abstract][Full Text] [Related]
26. [Immunophenotypes and gene mutations in colorectal precancerous lesions and adenocarcinoma].
Huang WT; Qiu T; Ling Y; Shi SS; Guo L; Zheng B; Lü N; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2013 Oct; 42(10):655-9. PubMed ID: 24433726
[TBL] [Abstract][Full Text] [Related]
27. Isolated loss of PMS2 expression in colorectal cancers: frequency, patient age, and familial aggregation.
Gill S; Lindor NM; Burgart LJ; Smalley R; Leontovich O; French AJ; Goldberg RM; Sargent DJ; Jass JR; Hopper JL; Jenkins MA; Young J; Barker MA; Walsh MD; Ruszkiewicz AR; Thibodeau SN
Clin Cancer Res; 2005 Sep; 11(18):6466-71. PubMed ID: 16166421
[TBL] [Abstract][Full Text] [Related]
28. BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.
Molinari F; Signoroni S; Lampis A; Bertan C; Perrone F; Sala P; Mondini P; Crippa S; Bertario L; Frattini M
Tumori; 2014; 100(3):315-20. PubMed ID: 25076244
[TBL] [Abstract][Full Text] [Related]
29. BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors.
Lubomierski N; Plotz G; Wormek M; Engels K; Kriener S; Trojan J; Jungling B; Zeuzem S; Raedle J
Cancer; 2005 Sep; 104(5):952-61. PubMed ID: 16015629
[TBL] [Abstract][Full Text] [Related]
30. Germline MLH1 Mutations Are Frequently Identified in Lynch Syndrome Patients With Colorectal and Endometrial Carcinoma Demonstrating Isolated Loss of PMS2 Immunohistochemical Expression.
Dudley B; Brand RE; Thull D; Bahary N; Nikiforova MN; Pai RK
Am J Surg Pathol; 2015 Aug; 39(8):1114-20. PubMed ID: 25871621
[TBL] [Abstract][Full Text] [Related]
31. Exclusive KRAS mutation in microsatellite-unstable human colorectal carcinomas with sequence alterations in the DNA mismatch repair gene, MLH1.
Zhao Y; Miyashita K; Ando T; Kakeji Y; Yamanaka T; Taguchi K; Ushijima T; Oda S; Maehara Y
Gene; 2008 Nov; 423(2):188-93. PubMed ID: 18692554
[TBL] [Abstract][Full Text] [Related]
32. Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.
Buchanan DD; Tan YY; Walsh MD; Clendenning M; Metcalf AM; Ferguson K; Arnold ST; Thompson BA; Lose FA; Parsons MT; Walters RJ; Pearson SA; Cummings M; Oehler MK; Blomfield PB; Quinn MA; Kirk JA; Stewart CJ; Obermair A; Young JP; Webb PM; Spurdle AB
J Clin Oncol; 2014 Jan; 32(2):90-100. PubMed ID: 24323032
[TBL] [Abstract][Full Text] [Related]
33. Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D.
Timmerman S; Van Rompuy AS; Van Gorp T; Vanden Bempt I; Brems H; Van Nieuwenhuysen E; Han SN; Neven P; Victoor J; Laenen A; Vergote I
Gynecol Oncol; 2020 Apr; 157(1):245-251. PubMed ID: 31980219
[TBL] [Abstract][Full Text] [Related]
34. MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers.
Simpkins SB; Bocker T; Swisher EM; Mutch DG; Gersell DJ; Kovatich AJ; Palazzo JP; Fishel R; Goodfellow PJ
Hum Mol Genet; 1999 Apr; 8(4):661-6. PubMed ID: 10072435
[TBL] [Abstract][Full Text] [Related]
35. Colorectal serrated adenocarcinoma shows a different profile of oncogene mutations, MSI status and DNA repair protein expression compared to conventional and sporadic MSI-H carcinomas.
García-Solano J; Conesa-Zamora P; Carbonell P; Trujillo-Santos J; Torres-Moreno D D; Pagán-Gómez I; Rodríguez-Braun E; Pérez-Guillermo M
Int J Cancer; 2012 Oct; 131(8):1790-9. PubMed ID: 22287190
[TBL] [Abstract][Full Text] [Related]
36. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas.
Esteller M; Levine R; Baylin SB; Ellenson LH; Herman JG
Oncogene; 1998 Nov; 17(18):2413-7. PubMed ID: 9811473
[TBL] [Abstract][Full Text] [Related]
37. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
[TBL] [Abstract][Full Text] [Related]
38. Causes and consequences of microsatellite instability in endometrial carcinoma.
Gurin CC; Federici MG; Kang L; Boyd J
Cancer Res; 1999 Jan; 59(2):462-6. PubMed ID: 9927063
[TBL] [Abstract][Full Text] [Related]
39. [The first molecular analysis of a Hungarian HNPCC family: a novel MSH2 germline mutation].
Czakó L; Tiszlavicz L; Takács R; Baradnay G; Lonovics J; Cserni G; Závodná K; Bartosova Z
Orv Hetil; 2005 May; 146(20):1009-16. PubMed ID: 15945244
[TBL] [Abstract][Full Text] [Related]
40. Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening.
Poynter JN; Siegmund KD; Weisenberger DJ; Long TI; Thibodeau SN; Lindor N; Young J; Jenkins MA; Hopper JL; Baron JA; Buchanan D; Casey G; Levine AJ; Le Marchand L; Gallinger S; Bapat B; Potter JD; Newcomb PA; Haile RW; Laird PW;
Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3208-15. PubMed ID: 18990764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
